FR2774589A3 - Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin - Google Patents
Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin Download PDFInfo
- Publication number
- FR2774589A3 FR2774589A3 FR9801794A FR9801794A FR2774589A3 FR 2774589 A3 FR2774589 A3 FR 2774589A3 FR 9801794 A FR9801794 A FR 9801794A FR 9801794 A FR9801794 A FR 9801794A FR 2774589 A3 FR2774589 A3 FR 2774589A3
- Authority
- FR
- France
- Prior art keywords
- mucopolysaccharidase
- escin
- compositions
- compositions according
- slimming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
La présente invention à pour objet de nouvelles compositions cosmétiques amincissantes. Dans ce qui suit, on désignera par le même adjectif "amincissantes" des compositions entraînant non seulement un amincissement, mais également une mobilisation des graisses entraînant un réel amaigrissement. The present invention relates to new slimming cosmetic compositions. In what follows, the same adjective will designate "slimming" compositions which cause not only a thinning, but also a mobilization of fats resulting in real weight loss.
La cellulite est la manifestation d'un certain déséquilibre métabolique au niveau des cellules adipeuses. II apparaît une prolifération des sites ss-adrénergiques sur la membrane des adipocytes, qui favorise la lipogenèse au détriment de la lipolyse. De plus, I'augmentation de la couche adipeuse s'accompagne d'un développement et d'une réticulation du tissu scléro-hyalin qui encapsule les adipocytes. Cellulite is the manifestation of a certain metabolic imbalance in the fat cells. There is a proliferation of ss-adrenergic sites on the adipocyte membrane, which promotes lipogenesis at the expense of lipolysis. In addition, the increase in the adipose layer is accompanied by the development and crosslinking of the sclero-hyaline tissue which encapsulates the adipocytes.
Les produits cosmétiques amincissants contiennent généralement des principes actifs stimulants la lipolyse. Or, les modifications structurales du tissu scléro-hyalin empêchent le contact entre les principes actifs et les sites récepteurs des adipocytes. Si ces actifs ont une bonne activité in vitro sur les adipocytes en culture, ils ont bien souvent des activités faibles ou inexistantes lorsqu'ils sont utilisés par les consommateurs. Slimming cosmetic products generally contain active ingredients that stimulate lipolysis. However, the structural modifications of the sclero-hyaline tissue prevent the contact between the active principles and the receptor sites of the adipocytes. If these active agents have a good activity in vitro on adipocytes in culture, they very often have weak or nonexistent activities when they are used by consumers.
II subsiste donc le besoin de compositions cosmétiques amincissantes capables à la fois d'attaquer le tissu scléro-hyalin et de stimuler la lipolyse. There therefore remains the need for slimming cosmetic compositions capable of both attacking the sclero-hyaline tissue and of stimulating lipolysis.
A la suite d'importantes recherches menées dans le domaine évoqué ci-dessus, la demanderesse a envisagé l'utilisation d'une mucopolysaccharidase en association avec de l'escine. Following significant research carried out in the field mentioned above, the Applicant has considered the use of a mucopolysaccharidase in association with escin.
Ainsi, conformément à l'objet de la présente invention, il est maintenant proposé de nouvelles compositions cosmétiques amincissantes qui sont essentiellement caractérisées par le fait qu'elles contiennent une mucopolysaccharidase et de l'escine. Thus, in accordance with the object of the present invention, new slimming cosmetic compositions are now proposed which are essentially characterized by the fact that they contain a mucopolysaccharidase and escin.
La mucopolysaccharidase permet par son activité enzymatique, d'éliminer la gangue qui entoure les adipocytes. L'escine masque les sites récepteurs p-adrénergiques, présents sur la membrane des adipocytes, et active ainsi la lipolyse. The mucopolysaccharidase allows by its enzymatic activity, to eliminate the gangue which surrounds the adipocytes. The escin masks the p-adrenergic receptor sites, present on the adipocyte membrane, and thus activates lipolysis.
Suivant un mode particulièrement préféré de la présente invention, la mucopolysaccharidase est une hyaluronidase, utilisée dans des proportions comprises entre 0,001 et 10 % en poids par rapport au poids total de la composition, lorsque l'activité enzymatique est de 300 000 Ul/g, et de préférence comprises entre 0,01 et 2 %. According to a particularly preferred embodiment of the present invention, the mucopolysaccharidase is a hyaluronidase, used in proportions of between 0.001 and 10% by weight relative to the total weight of the composition, when the enzymatic activity is 300,000 IU / g, and preferably between 0.01 and 2%.
Selon un mode de réalisation avantageux de l'invention,
'escine est apportée sous forme d'extrait de marron d'lnde. La proportion en escine des compositions de l'invention sont de préférence comprises entre 0,001 et 50 % en poids par rapport au poids total de la composition, et mieux encore, entre 0,1 et 5 %.According to an advantageous embodiment of the invention,
escine is brought in the form of extract of horse chestnut The steep proportion of the compositions of the invention are preferably between 0.001 and 50% by weight relative to the total weight of the composition, and better still, between 0.1 and 5%.
Les compositions selon l'invention peuvent en outre contenir tous les constituants classiquement utilisés, notamment autres actifs amincissants, dans les compositions cosmétiques amincissantes tels que par exemple les dérivés xanthiques (caféine, théophylline), les dérivés du silicium organique (monométhylsilanétriol, diméthyl silanol}. Leur proportion préférentielle est comprise entre 1 et 20 % en poids par rapport au poids total de la composition, et mieux encore entre 1 et 10 %. The compositions according to the invention may also contain all the constituents conventionally used, in particular other slimming active agents, in cosmetic slimming compositions such as for example the xanthic derivatives (caffeine, theophylline), the organic silicon derivatives (monomethylsilanetriol, dimethyl silanol). Their preferred proportion is between 1 and 20% by weight relative to the total weight of the composition, and better still between 1 and 10%.
La composition selon l'invention peut se présenter sous toutes les formes galéniques classiquement utilisées dans les compositions cosmétiques. The composition according to the invention can be in all the galenical forms conventionally used in cosmetic compositions.
Des exemples concrets, mais nullement limitatifs, illustrant l'invention vont maintenant être donnés. Concrete, but in no way limiting, examples illustrating the invention will now be given.
Exemple 1:
Mucopolysaccharidase 0, 1%
Escine 2%
Stéareth-20 0,2 %
Méthyl paraben 0,25%
Chlorure de calcium 0,01%
Chlorure de magnésium 0,01 %
Eau qsp 100 %
Stéareth- 2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1 %
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 %
Exemple 2:
Mucopolysaccharidase 0,05 %
Escine 0,1 %
Silicium 2%
Stéareth-20 0,2 %
Méthyl paraben 0,25 %
Chlorure de calcium 0,01 %
Chlorure de magnésium 0,01 %
Eau qsp. 100 %
Stéareth-2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1%
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 %
Exemple 3
Mucopolysaccharidase 0,05 %
Escine 0,1 %
Théophylline 0,5 %
Caféine 0,5 %
Stéareth-20 0,2 %
Méthyl paraben 0,25 %
Chlorure de calcium 0,01 %
Chlorure de magnésium 0,01 %
Eau qsp. 100 %
Stéareth-2 1,3 %
Alcool cétyl stéarylique 4%
Myristate de myristyle 4 %
Myristate d'isopropyle 4 %
Glycérine 1%
Diméthicone 0,5 %
Alcools lanoliques 0,5 %
Propyl paraben 0,25 % Example 1:
Mucopolysaccharidase 0, 1%
Escine 2%
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs 100%
Steareth- 2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%
Example 2:
Mucopolysaccharidase 0.05%
Escin 0.1%
2% silicon
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs. 100%
Steareth-2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%
Example 3
Mucopolysaccharidase 0.05%
Escin 0.1%
Theophylline 0.5%
Caffeine 0.5%
0.2% steareth-20
0.25% methyl paraben
0.01% calcium chloride
Magnesium chloride 0.01%
Water qs. 100%
Steareth-2 1.3%
Cetyl stearyl alcohol 4%
Myristyl myristate 4%
Isopropyl myristate 4%
Glycerin 1%
Dimethicone 0.5%
Lanolic alcohols 0.5%
Propyl paraben 0.25%
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9801794A FR2774589B3 (en) | 1998-02-10 | 1998-02-10 | SLIMMING COSMETIC COMPOSITIONS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9801794A FR2774589B3 (en) | 1998-02-10 | 1998-02-10 | SLIMMING COSMETIC COMPOSITIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2774589A3 true FR2774589A3 (en) | 1999-08-13 |
FR2774589B3 FR2774589B3 (en) | 2000-01-07 |
Family
ID=9522977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9801794A Expired - Lifetime FR2774589B3 (en) | 1998-02-10 | 1998-02-10 | SLIMMING COSMETIC COMPOSITIONS |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2774589B3 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1541127A1 (en) * | 2003-12-10 | 2005-06-15 | L'oreal | Use of modulators of aquaglyceroporins as slimming agents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2720510A1 (en) * | 1976-05-07 | 1977-11-24 | Biotherm | COSMETIC AGENT WITH SLIMMING AND ANTICELLULITIS EFFECT |
DE2729010A1 (en) * | 1976-07-02 | 1978-01-12 | Ana Lab Sa | MEDICINAL PRODUCTS FOR THE TREATMENT OF CELLULITE AND EXCESSIVE FAT |
FR2400902A1 (en) * | 1977-08-22 | 1979-03-23 | Ana Laboratoires | Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition |
-
1998
- 1998-02-10 FR FR9801794A patent/FR2774589B3/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2720510A1 (en) * | 1976-05-07 | 1977-11-24 | Biotherm | COSMETIC AGENT WITH SLIMMING AND ANTICELLULITIS EFFECT |
DE2729010A1 (en) * | 1976-07-02 | 1978-01-12 | Ana Lab Sa | MEDICINAL PRODUCTS FOR THE TREATMENT OF CELLULITE AND EXCESSIVE FAT |
FR2400902A1 (en) * | 1977-08-22 | 1979-03-23 | Ana Laboratoires | Mucopolysaccharidase-aescin-acetazolamide compsns. - for treating cellulitis and excess fat deposition |
Non-Patent Citations (2)
Title |
---|
R. MAFFEI FACINO: "Anti-Elastase and Anti-Hyaluronidase Activities of Saponins and Sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: Factors Contributing to their Efficacy in the Treatment of Venous Insufficiency", ARCH. PHARM., vol. 328, no. 10, 1995, Weinheim Germany), pages 720 - 724, XP002082552 * |
R. MAFFEI FACINO: "Efficacy of Topically Applied Hedera Helix L. Saponins for Treatment of Liposclerosis (so-called "Cellulitis")", ACTA THERAPEUTICA, vol. 16, no. 4, 1990, pages 337 - 349, XP002082551 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1541127A1 (en) * | 2003-12-10 | 2005-06-15 | L'oreal | Use of modulators of aquaglyceroporins as slimming agents |
FR2863492A1 (en) * | 2003-12-10 | 2005-06-17 | Oreal | USE OF AQUAGLYCEROPORIN MODULATORS AS SLIMMING |
Also Published As
Publication number | Publication date |
---|---|
FR2774589B3 (en) | 2000-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4863725A (en) | Novel clear oil-free moisturizer composition | |
JP4601898B2 (en) | Topical lightening composition and method of use | |
US8394363B2 (en) | Cosmetic rinsable mask type composition for skin care | |
FR2669537A1 (en) | SLIMMING COMPOSITION BASED ON ALPHA-2-BLOCKERS. | |
FR2499405A1 (en) | SLIMMING AND ANTI-CELLULAR COSMETIC COMPOSITION BASED ON A PLANT EXTRACT CONTAINING SAPONINS, AN EXTRACT FROM ARNICA MONTANA L. AND A COLA NUT EXTRACT AND METHOD OF APPLICATION THEREOF | |
JP4182183B2 (en) | Slimming skin cosmetics | |
KR20110014221A (en) | Method and compositions for improving skin and body appearance | |
JP2001506240A (en) | Cosmetic cleansing skin care preparation containing plant extract and seaweed extract | |
FR2788058A1 (en) | SLIMMING COSMETIC COMPOSITIONS | |
CN110215407A (en) | A kind of anti-ageing compact composition and its cosmetics and application | |
EP0655235B1 (en) | Slimming composition | |
EP0450669B1 (en) | Cosmetic or dermatological slimming or anticellulitis composition containing cola extracts into liposomes | |
JP2000229834A (en) | Cosmetic | |
US20100189754A1 (en) | Oil Based Composition For External Use On Skin For Enhancing Percutaneous Absorption | |
CA1091581A (en) | Cosmetic composition against cellulitis and for slenderizing | |
FR2725898A1 (en) | TOPICAL APPLICATION PRODUCT CONTAINING A LIPASE AND A HYDROXYACID PRECURSOR | |
FR2774589A3 (en) | Cosmetic slimming compositions having lipolytic activity, containing mucopolysaccharidase and escin | |
FR2748659A1 (en) | TOPICAL SLIMMING COMPOSITION | |
JP3537671B2 (en) | Lipolysis accelerator and skin cosmetic for slimming | |
FR2758724A1 (en) | Controlling cellulite and fat deposition | |
JPH0528203B2 (en) | ||
EP0971722B1 (en) | An aphrodisiac for application to the sexual organs | |
EP1551365A1 (en) | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor | |
JP2001163762A (en) | Sliming agent | |
JP4842170B2 (en) | Solid powder cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CL | Concession to grant licences | ||
CL | Concession to grant licences | ||
AU | Other action affecting the ownership or exploitation of an industrial property right |